Literature DB >> 9253530

ECT for the treatment of Huntington's disease: a case study.

M D Beale1, C H Kellner, P Gurecki, J T Pritchett.   

Abstract

We report a 56-year-old man with Huntington's disease whose chorea substantially improved after treatment with electroconvulsive therapy (ECT). ECT should be considered for medically refractory cases of movement disorders, especially those with severe disability.

Entities:  

Mesh:

Year:  1997        PMID: 9253530

Source DB:  PubMed          Journal:  Convuls Ther        ISSN: 0749-8055


  6 in total

1.  Worsening of movement disorder following treatment with electroconvulsive therapy in a patient with Huntington's disease.

Authors:  Hesitha Abeysundera; Allan Campbell; Shanthi Sarma
Journal:  BMJ Case Rep       Date:  2019-08-10

2.  Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice.

Authors:  Mohamed R Mughal; Akanksha Baharani; Srinivasulu Chigurupati; Tae Gen Son; Edmund Chen; Peter Yang; Eitan Okun; Thiruma Arumugam; Sic L Chan; Mark P Mattson
Journal:  Hum Mol Genet       Date:  2010-11-24       Impact factor: 6.150

3.  Electroconvulsive seizure inhibits the mTOR signaling pathway via AMPK in the rat frontal cortex.

Authors:  Se Hyun Kim; Hyun Sook Yu; Seonghoo Huh; Ung Gu Kang; Yong Sik Kim
Journal:  Psychopharmacology (Berl)       Date:  2021-10-30       Impact factor: 4.530

4.  Ect in neurological counditions.

Authors:  K Girish; B N Gangadhar; N Janakiramaiah
Journal:  Indian J Psychiatry       Date:  2002-07       Impact factor: 1.759

5.  Electroconvulsive therapy for severe depression, psychosis and chorea in a patient with Huntington's disease: case report and review of the literature.

Authors:  Walied Mowafi; Jon Millard
Journal:  BJPsych Bull       Date:  2021-04

6.  Electroconvulsive Seizures Induce Autophagy by Activating the AMPK Signaling Pathway in the Rat Frontal Cortex.

Authors:  Se Hyun Kim; Hyun Sook Yu; Soyoung Park; Hong Geun Park; Yong Min Ahn; Ung Gu Kang; Yong Sik Kim
Journal:  Int J Neuropsychopharmacol       Date:  2020-03-10       Impact factor: 5.176

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.